BRII-835

Phase 2Small molecule

BBrii Biosciences Limited

BRII-835 is one of 26 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 3

Incivek

Vertex Pharmaceuticals

Preclinical

10 4

Intron a

Sanofi

Preclinical

7 5

Roferon-a

Roche

Preclinical

3 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

SOF/VEL

Gilead

Preclinical

4 9

BRII-835

BBrii Biosciences Limited

Phase 2

3 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Chronic Hepatitis

NCT06491563

Q3 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06650852

Clinical

Trials by Indication[1]

Chronic Hepatitis3 trials

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT06491563·150 enrolled

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

Completed·BBrii Biosciences Limited·Phase 2·NCT04749368·91 enrolled

Combination Therapy1 trial

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT05970289·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BRII-835. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BRII-835 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BRII-835. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brii Biosciences Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBrii Biosciences Limited

BRII-835

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Hepatitis3 trials

Combination Therapy1 trial

References

Drug Info

Quick Facts

Related News